Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 7/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.40 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3949661 | 1.00 | AKR1C3 (0.45) | AKR1C3PTGS2MAOBAKR1C2AKR1C1 | |
| SCHEMBL3949667 | 1.00 | AKR1C3 (0.45) | AKR1C3PTGS2MAOBAKR1C2AKR1C1 | |
| SCHEMBL3943635 | 0.80 | ALDH1A1 (0.55) | — | |
| SCHEMBL3943639 | 0.80 | ALDH1A1 (0.55) | — | |
| SCHEMBL3943637 | 0.80 | ALDH1A1 (0.55) | — | |
| SCHEMBL28605956 | 0.78 | ENPP2 (0.45) | AKR1C3PTGS2MAOB | |
| SCHEMBL3940758 | 0.78 | PTGS2 (0.58) | AKR1C3PTGS2AKR1C2AKR1C1 | |
| SCHEMBL3940765 | 0.78 | PTGS2 (0.58) | AKR1C3PTGS2AKR1C2AKR1C1 | |
| SCHEMBL4093138 | 0.77 | ALOX15 (0.45) | MAOB | |
| SCHEMBL4093145 | 0.77 | ALOX15 (0.45) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-2050734-A1 | PENTADIENAMIDE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | PRMT1, REN, NGLY1 | AKR1C3 486/4885PTGS2 3329/4885MAOB 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.